Neuroimaging and cognition in parkinson's disease dementia

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The prevalence of cognitive impairment and dementia in Parkinson's disease (PD) is high and can potentially occur as the result of multiple differing pathologies. Neuroimaging has provided evidence of decreased cortical volume, increased white matter diffusion changes, and decreased resting metabolic activity that appears to begin prior to the onset of dementia in PD patients. Cognitive impairment has been found to be associated with multiple neurotransmitter transmission deficiencies, including dopamine and acetylcholine, indicating a widespread neurotransmitter dysfunction in PD-related dementia. Findings of increased Pittsburgh Compound B (PiB) binding in subjects with Lewy Body Disease (LBD) compared with Parkinson's disease and dementia (PDD) may explain phenotype differences in the spectrum of Dementia with Lewy Bodies (DLB), and show promise in guiding future therapeutic trials aimed at this disease. Advances in neuroimaging now allow for the detection of volumetric, pharmacologic, and pathological changes that may assist in the diagnosis and prediction of cognitive impairment in Parkinson's patients so that better evaluation of disease progression and treatment can be obtained.

Original languageEnglish (US)
Pages (from-to)646-653
Number of pages8
JournalBrain Pathology
Volume20
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Neuroimaging
Cognition
Parkinson Disease
Dementia
Lewy Body Disease
Neurotransmitter Agents
Acetylcholine
Disease Progression
Dopamine
Pathology
Phenotype
Therapeutics
Cognitive Dysfunction

Keywords

  • Cognition
  • Dementia
  • Magnetic resonance imaging (MRI)
  • Neuroimaging
  • Parkinson's Disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Neuroimaging and cognition in parkinson's disease dementia. / Silbert, Lisa; Kaye, Jeffrey.

In: Brain Pathology, Vol. 20, No. 3, 05.2010, p. 646-653.

Research output: Contribution to journalArticle

@article{0f2e1d32471548ceaff9aa3941bba5a0,
title = "Neuroimaging and cognition in parkinson's disease dementia",
abstract = "The prevalence of cognitive impairment and dementia in Parkinson's disease (PD) is high and can potentially occur as the result of multiple differing pathologies. Neuroimaging has provided evidence of decreased cortical volume, increased white matter diffusion changes, and decreased resting metabolic activity that appears to begin prior to the onset of dementia in PD patients. Cognitive impairment has been found to be associated with multiple neurotransmitter transmission deficiencies, including dopamine and acetylcholine, indicating a widespread neurotransmitter dysfunction in PD-related dementia. Findings of increased Pittsburgh Compound B (PiB) binding in subjects with Lewy Body Disease (LBD) compared with Parkinson's disease and dementia (PDD) may explain phenotype differences in the spectrum of Dementia with Lewy Bodies (DLB), and show promise in guiding future therapeutic trials aimed at this disease. Advances in neuroimaging now allow for the detection of volumetric, pharmacologic, and pathological changes that may assist in the diagnosis and prediction of cognitive impairment in Parkinson's patients so that better evaluation of disease progression and treatment can be obtained.",
keywords = "Cognition, Dementia, Magnetic resonance imaging (MRI), Neuroimaging, Parkinson's Disease",
author = "Lisa Silbert and Jeffrey Kaye",
year = "2010",
month = "5",
doi = "10.1111/j.1750-3639.2009.00368.x",
language = "English (US)",
volume = "20",
pages = "646--653",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Neuroimaging and cognition in parkinson's disease dementia

AU - Silbert, Lisa

AU - Kaye, Jeffrey

PY - 2010/5

Y1 - 2010/5

N2 - The prevalence of cognitive impairment and dementia in Parkinson's disease (PD) is high and can potentially occur as the result of multiple differing pathologies. Neuroimaging has provided evidence of decreased cortical volume, increased white matter diffusion changes, and decreased resting metabolic activity that appears to begin prior to the onset of dementia in PD patients. Cognitive impairment has been found to be associated with multiple neurotransmitter transmission deficiencies, including dopamine and acetylcholine, indicating a widespread neurotransmitter dysfunction in PD-related dementia. Findings of increased Pittsburgh Compound B (PiB) binding in subjects with Lewy Body Disease (LBD) compared with Parkinson's disease and dementia (PDD) may explain phenotype differences in the spectrum of Dementia with Lewy Bodies (DLB), and show promise in guiding future therapeutic trials aimed at this disease. Advances in neuroimaging now allow for the detection of volumetric, pharmacologic, and pathological changes that may assist in the diagnosis and prediction of cognitive impairment in Parkinson's patients so that better evaluation of disease progression and treatment can be obtained.

AB - The prevalence of cognitive impairment and dementia in Parkinson's disease (PD) is high and can potentially occur as the result of multiple differing pathologies. Neuroimaging has provided evidence of decreased cortical volume, increased white matter diffusion changes, and decreased resting metabolic activity that appears to begin prior to the onset of dementia in PD patients. Cognitive impairment has been found to be associated with multiple neurotransmitter transmission deficiencies, including dopamine and acetylcholine, indicating a widespread neurotransmitter dysfunction in PD-related dementia. Findings of increased Pittsburgh Compound B (PiB) binding in subjects with Lewy Body Disease (LBD) compared with Parkinson's disease and dementia (PDD) may explain phenotype differences in the spectrum of Dementia with Lewy Bodies (DLB), and show promise in guiding future therapeutic trials aimed at this disease. Advances in neuroimaging now allow for the detection of volumetric, pharmacologic, and pathological changes that may assist in the diagnosis and prediction of cognitive impairment in Parkinson's patients so that better evaluation of disease progression and treatment can be obtained.

KW - Cognition

KW - Dementia

KW - Magnetic resonance imaging (MRI)

KW - Neuroimaging

KW - Parkinson's Disease

UR - http://www.scopus.com/inward/record.url?scp=77950839159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950839159&partnerID=8YFLogxK

U2 - 10.1111/j.1750-3639.2009.00368.x

DO - 10.1111/j.1750-3639.2009.00368.x

M3 - Article

C2 - 20522090

AN - SCOPUS:77950839159

VL - 20

SP - 646

EP - 653

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 3

ER -